Under the Paperwork Reduction Act of 1995, no persons are required to resp

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT
(Not for submission under 37 CFR 1.99)

Application Number		10809638				
Filing Date		2004-03-24				
First Named Inventor	Jun FENG					
Art Unit		1624				
Examiner Name	Kahsa	ay Habte				
Attornov Docket Numb	or	DDD4 5004 C2				

				Attorney Docket Numb			DPP4-5004-C3					
					U.S.	PATENTS				Remove	_	
Examiner Initial*	Cite No	Patent Number	Kind Code ¹	Issue [Issue Date Name of Patentee or Applicant Rele		Releva	es,Columns,Lines where vant Passages or Relevant res Appear				
	1											
If you wisl	h to a	dd additional U.S. Pater	nt citatio	n inform	ation pl	ease click the	Ad	id button.		Add		
			U.S.P.	ATENT	APPLI	CATION PUBL	LIC	ATIONS		Remove		
Examiner Initial*	Cite No	Publication Number	Kind Code ¹	Publica Date	Ication Name of Patentee of Applicant Rel		Releva	ges,Columns,Lines where levant Passages or Relevant ures Appear				
	1											
If you wisl	h to a	dd additional U.S. Publi	shed Ap	plication	citatio	n information p	olea	se click the Ad	button.	Add		
				FOREIG	SN PAT	ENT DOCUM	EN	ITS		Remove		
Examiner Initial*	Cite No	Foreign Document Number ³	Country Code ²		Kind Code ⁴	Publication Date	A	ame of Patente pplicant of cited ocument	e or v	vhere Rele	or Relevant	TE
	1	EP 1197799 A1	EP			2002-04-17	Fı	uji Photo Film Co.	, Ltd.			
	2	GB 2143542 A	GB			1985-02-13	CI	IBA-GEIGY AG,				
If you wisi	h to a	dd additional Foreign P	atent Do	cument	citation	information pl	l lea:	se click the Add	button	Add		_
			HOL	DATE		RATURE DO		MENTE		Remove		

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

pplication Number		10809638		
iling Date		2004-03-24		
rst Named Inventor Jun F		ENG		
rt Unit		1624		
xaminer Name	Kahsa	ny Hable		
ttorney Docket Number		DPP4-5004-C3		

Examiner Initials*	Cite No	include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposaum, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where publisher.	Ţ5
	1	Abdel-Fattah et al. Indian Journal of Helterocyclic Chemistry (1999), 8(3), 177-182. (Abstract, 2 pages).	
	2	Barnela et al. Indian Journal of Chemistry Section B. Organic Chemistry Including Medicinal Chemistry (1985), 258(7), 709-11. (Abstract 2 pages).	
	3	Soliman et al. Journal of the Chemical Society of Pakistan (1986), 8(2), 97-106. (Abstract 2 pages).	Г
	4	Sammour et al. Egyptian Journal of Chemistry (1979) Volume Date 1976, 19(6), 1109-16. (Abstract 2 pages).	
If you wish	to a	dd additional non-patent literature document citation information please click the Add button Add	_

A

E

EXAMINER SIGNATURE Date Considered

Examiner Signature Date Considered Date Considered | Date Considered |

"EXAMINER: Initial if reference considered, whether or not citation is in conformance with MFEP 809. Draw line through a citation if not in conformance and not considered. Include copy of his form with next communication to applicant.

See You Code of USPTO Pears Documents at your USETO_DOLY or NETP 80 (A). Takes often that issued the document, by the two-letter code (WIPO Standard ST.3). For the parties pears for comment, the wold and to the year of the region of the Emporer many preceded the senial number of the parties countries.

Your of document by the appropriate symbols as saticated on the document under WIPO Standard ST.1 64 possible. *Applicant is to place a check many labels.

*Experise languages retrainations in standard.**

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

Application Number		10809638		
Filing Date		2004-03-24		
First Named Inventor Jun FE		ENG		
Art Unit		1624		
Examiner Name	Kahsa	ay Hable		
Attorney Docket Number		DPP4-5004-C3		

CERTIFICATION STATEMENT

Please see 37	CFR 1.97	and 1.98 to	make the a	ppropriate sele	ction(s):
---------------	----------	-------------	------------	-----------------	-----------

That each item of information contained in the information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filling of the information disclosure statement. Sea 37 CFF 1.37(e)(1).

OR

That no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquity, no item of information contained in the information disclosure statement was known to any individual designated in 37 CFR 156(c) more than three months prior to the filing of the information disclosure statement. See 37 CFR 157(e).

- See attached certification statement.
- Fee set forth in 37 CFR 1.17 (p) has been submitted herewith.
- _ ...

SIGNATURE

A signature of the applicant or representative is required in accordance with CFR 1.33, 10.18. Please see CFR 1.4(d) for the form of the signature.

Signature	/Mitchell R. Brustein/	Date (YYYY-MM-DD)	2007-04-05
Name/Drint	Misshell D. Douglein	Dogistration Number	20 204

This collection of information is required by 3T CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is for life and by the USPTO to process) an application. Confidentiality is governed by \$5 U.S. C. 12.0 and 37 CFR
1.14. This collection is estimated to take it hour to complete, including gathering, preparing and submitting the completed application from the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Petert and Tradenski of Time; A. (See a considerable of the Chief Information Officer, U.S. Petert and Tradenski of Time; O.S. (Assendin, V.S. 2313-1450). DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. 80x 1450, Alexandria, V.A. 2313-1450.

Privacy Act Statement

The Privacy Act of 1974 (P. L. 93-579) requires that you be given certain information in connection with your submission of the stackhold from related to a patient application or patient. Accordingly, pursuant to the requirements of the Act, places be advised that (1) the general authority for the collection of this information is 35 U.S.C. 2(b)(2); (2) familishing of the information solicided is couldrain; and (3) the primoral pursuance for which the information is used by the U.S. Patient and Trademan Coffice is to process and/or examine your submission related to a patient agricultant or patient. If you do not furnish the requested process and/or examine your submission related to a patient agricultant or patient. If you do not furnish the requested results of the patient of the patient and the patient of the patient

The information provided by you in this form will be subject to the following routine uses:

- The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether the Freedom of Information Act requires disclosure of these record s.
 - A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement negotiation.
 - A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record perfains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
 - A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974, as amended, pursuant to 5 U.S.C. 552(m).
 - A record related to an International Application filed under the Patent Cooperation Treaty in this system of records
 may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant
 to the Patent Cooperation Treaty.
- A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
- 7. A record from this system of records may be discbesed, as a routine use, to the Administrator, General Services, or hisher designed, cuting an inspection of records conducted by GSA as part of that agency's responsibility to recommend improvements in records management practices and programs, under authority of 4d U.S.C. 2904 and 2906. Such disclosure shall be made in accordance with the GSA regulations governing inspection of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make determinations about individuals.
- A record from this system of records may be disclosed, as a routine use, to the public after either publication of the
 application pursuant to 35 U.S.C. 12(2) or issuance of a patent pursuant to 35 U.S.C. 151. Further, a record may be
 disclosed, subject to the limitations of 37 CFR 1.14, as a routine use, to the public if the record was filled in application
 which became abandoned or in which the proceedings were terminated and which application is referenced by either a
 published application, an application open to public inspections or as issued patent.
 - A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.